Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy  by Moshfegh, Khatereh et al.
Platelet Inhibitors
Antiplatelet Effects of Clopidogrel Compared
With Aspirin After Myocardial Infarction:
Enhanced Inhibitory Effects of Combination Therapy
Khatereh Moshfegh, PHD, Maurice Redondo, MD,* Friedgard Julmy, Walter A. Wuillemin, MD, PHD,*
Mathias U. Gebauer, MD, Andre´ Haeberli, PHD, Beat J. Meyer, MD
Bern, Switzerland
OBJECTIVES We sought to compare the inhibitory effects of the combination of two doses of aspirin plus
clopidogrel with either drug alone on platelet aggregation and activation.
BACKGROUND Enhanced platelet inhibitory effects of clopidogrel by aspirin on platelet aggregation and
activation are suggested by experimental studies but have not been shown in humans.
METHODS The effects of clopidogrel 75 mg or aspirin 100 (300) mg on platelet aggregation and
activation by flow cytometry after stimulation with various agonists were determined in 30
patients with a past history of myocardial infarction.
RESULTS Clopidogrel alone or in combination with aspirin markedly inhibited adenosine diphosphate
(ADP)-mediated platelet aggregation compared with monotherapy with aspirin (24.6 6 3.3%
or 26.6 6 2.7% vs. 44.7 6 2.9%; p , 0.001). Combined treatment significantly inhibited
collagen-induced aggregation compared with aspirin and clopidogrel (16.4 6 2.4%, 36.5 6
4.2% and 59.3 6 5.1%, respectively; p , 0.001) and resulted in considerable inhibition of
aggregation induced by thrombin receptor agonist peptide (TRAP, p , 0.03). Clopidogrel
with or without aspirin significantly suppressed expression of platelet activation markers CD
62p, CD 63 and PAC-1 after stimulation with ADP or thrombin (p , 0.001). In addition,
the combined treatment was more effective than either agent alone after activation with low
dose thrombin (p , 0.05). Both doses of aspirin equally potentiated the platelet inhibitory
effects of clopidogrel.
CONCLUSIONS In this prospective clinical ex vivo platelet study, clopidogrel was more effective than aspirin
in inhibiting ADP-mediated platelet aggregation and activation. Clopidogrel in combination
with aspirin showed synergistic inhibitory effects after stimulation with collagen and
thrombin compared with monotherapies. Thus, this dual antiplatelet treatment strategy
deserves further evaluation in clinical trials for secondary prevention of acute myocardial
infarction or unstable angina. (J Am Coll Cardiol 2000;36:699–705) © 2000 by the
American College of Cardiology
Antiplatelet therapy reduces recurrent ischemic events in
patients with cardiovascular disease (1). Aspirin, although
most widely used, cost-effective and safe, is a weak platelet
inhibitor affecting only the cyclooxygenase pathway. De-
spite long-term aspirin use, a large number of patients
continue to have recurrent events associated with bad
outcomes (2). Recurrent events in such patients may reflect
natural progression of atherosclerosis or they take place
through mechanisms that overcome the aspirin-induced
inhibition of platelet function. This may occur by exposure
of platelets to high local concentrations of strong agonists,
such as collagen or thrombin, or by high levels of platelet
released adenosine diphosphate (ADP) or thromboxane A2
from nonplatelet sources (3).
Recent clinical trials with intravenous platelet glycopro-
tein IIb/IIIa (GP IIb/IIIa) receptor blockers have demon-
strated that aspirin monotherapy has been improved upon
(4). Further evidence for a combined antiplatelet treatment
strategy comes from studies with aspirin and ticlopidine.
They have been shown to lower the risk of subacute stent
thrombosis and to be safer when compared with conven-
tional anticoagulant therapy (5–8) and aspirin alone (6). In
addition, data with clopidogrel, a new thienopyridine de-
rivative lacking the serious hematological side effects of
ticlopidine, suggest that its combination with aspirin may be
an alternative treatment after coronary stent placement (9).
In patients with cardiovascular disease, clopidogrel alone
was slightly more effective than aspirin in reducing the
combined risk of ischemic stroke, myocardial infarction
(MI) or vascular death (10). Although the effects of simul-
taneous administration of clopidogrel and aspirin on platelet
aggregation and function in patients after MI has not been
studied, experimental data suggest synergy between both
drugs (11–13).
In our study we compared the inhibitory effects of the
combination of aspirin and clopidogrel with either drug
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alone on platelet aggregation and platelet activation induced
by various agonists in patients with MI. In addition, we
analyzed whether the dose of aspirin was affecting the
inhibitory potential of the combination therapy.
METHODS
Patient selection. Thirty consecutive patients with stable
coronary artery disease and a history of MI older than three
months on chronic aspirin treatment were recruited at the
cardiology outpatients clinics at the University Hospital
Bern. Patients between 37 and 77 years of age without
hemorrhagic disorders were enrolled in the study after
written informed consent was obtained. Patient character-
istics were as follows: former smokers 57%; hypertension
47%; diabetes 17%; mean total cholesterol 5.2 6 0.9
mmol/L; baseline medication was not changed throughout
the study and included lipid lowering drugs in 40%, beta-
adrenergic blocking agents in 50%, angiotensin-converting
enzyme inhibitors in 47% and calcium antagonists in 27%.
The study was performed according to the Declaration of
Helsinki and followed protocol approval by the Institutional
Review Board of the University Hospital Bern.
Study design and timing of blood collection. Patients
(n 5 30) were assigned to five consecutive treatment
periods. At the end of each treatment period, venous blood
samples for platelet activation and aggregation experiments
were collected. The study consisted of an initial one-week
run-in period (phase 1) where patients were treated with
aspirin 100 mg daily. Then, clopidogrel 75 mg daily for
seven days was added to aspirin 100 mg (phase 2). After a
washout period of seven days for clopidogrel and aspirin,
clopidogrel 75 mg daily was given alone for seven days
(phase 3). After a washout period for clopidogrel and
treatment with aspirin 300 mg for 14 days, the fourth
measurements were performed (n 5 12, phase 4). The final
phase (n 5 12) consisted of combined treatment with
aspirin 300 mg and clopidogrel 75 mg daily for seven days.
The Institutional Review Board felt that temporary discon-
tinuation of aspirin and clopidogrel for an untreated control
group was ethically not acceptable since it would add little
additional information to this comparative study. Treat-
ment periods were chosen to assess effects at the steady state
of chronic drug administration (14). Since platelet functions
return to normal approximately 10 days after stopping
therapy with both drugs, corresponding to the lifespan of
platelets, washout periods for either drug consisted of 14
days between phases 2 and 3 and 3 and 4, respectively.
Studies on Platelets
Platelet aggregation in platelet rich plasma. Thirty mL
of whole blood were anticoagulated with 3.8% (wt/vol)
sodium citrate (1 vol:9 vol). Platelet-rich plasma (PRP) was
prepared by centrifugation at 800 3 g for 2 min at room
temperature. Platelet count of PRP was adjusted to
300,000/mL using platelet-poor plasma (PPP) obtained by
further centrifugation (2,000 3 g 15 min). The aggregome-
ter (PAYTON, Dual Channel, Baxter, Switzerland) was
calibrated for the difference in light transmission between
PPP and PRP. Platelets were stimulated with ADP (Sigma,
Switzerland) at concentrations of 3, 6 and 20 mmol/L, with
collagen type I (Horm, Nycomed, Munich, Germany) at
concentrations of 1.5, 4 and 40 mg/mL and with a thrombin
receptor agonist peptide (TRAP 14-mer, SFLLRNPND-
KYEPF, Fluka, Switzerland) at concentrations of 8, 10 and
15 mmol/L. Results were expressed as percent aggregation
calculated linearly as percent light transmission between the
optical densities of PPP and PRP. If necessary, collagen was
added in additional doses to facilitate construction of a
dose-response curve and calculation of ED50 values (de-
fined as the concentration at which there is 50% aggrega-
tion). Arachidonic acid-induced aggregation (1 mmol/L,
Servotec) was used to assess aspirin intake.
Murine mAbs used in this study. Platelet alpha-granule
secretion was assessed using an anti-P-selectin mAb, CD
62p (P-selectin, Becton Dickinson); platelet lysosome de-
granulation was assessed using mAb CD 63 (Immunotech).
Platelets were identified in PRP and whole blood using
mAb 7H2, directed against GP IIIa (kindly provided by Dr.
B. S. Coller, Mount Sinai Hospital, New York). PAC-1, a
murine IgM-kappa mAb, binding to a conformation-
dependent determinant on activated GP IIb/IIIa complexes
unoccupied with adhesive proteins, was purchased from
Becton Dickinson.
Flow cytometry for measurement of platelet surface
antigen expression. The procedures for ex vivo detection
of activated platelets have been described previously by
Michelson (15), Warkentin (16) and us (17). Platelet-rich
plasma was prepared immediately after venipuncture of
8.5 mL blood drawn into a 10 mL Monovette containing
1.5 mL of acid citrate dextrose (citric acid 38 mmol/L,
sodium citrate 74.8 mmol/L, dextrose 124 mmol/L; pH
5.0) by centrifugation with 8003g for 2 min at room
temperature. Platelets were counted (Sysmex K-1000) and
adjusted to 300,000/mL with sterile filtered modified Ty-
rode’s buffer (137 mmol/L NaCl, 2.8 mmol/L KCl, 1
mmol/L MgCl2, 12 mmol/L NaHCO3, 0.4 mmol/L
Na2HPO4, 0.35% bovine serum albumin, 10 mmol/L
HEPES, 5.5 mmol/L glucose, pH 7.4). Platelet-rich plasma
was then diluted 1:4 with modified Tyrode’s buffer. This
dilution of blood into buffer decreases the platelet concen-
tration, thereby reducing platelet-to-platelet interaction af-
Abbreviations and Acronyms
ADP 5 adenosine diphosphate
GP IIb/IIIa 5 glycoprotein IIb/IIIa
MI 5 myocardial infarction
PBS 5 phosphate buffered saline
PPP 5 platelet-poor plasma
PRP 5 platelet-rich plasma
TRAP 5 thrombin receptor agonist peptide
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ter addition of agonists (15). Diluted PRP was aliquoted
into polypropylene tubes containing the agonists at the
following final concentrations: ADP 0.1 mmol/L to 100
mmol/L (Sigma), human and equine fibrillar collagen type I
25 mg/mL to 75 mg/mL (Horm, Nycomed) and thrombin
0.05 U/mL to 0.5 U/mL (Diagnotec). To inhibit fibrin
polymerization, the thrombin aliquots contained additional
2 mmol/L (final concentration) of the peptide H-Gly-Pro-
Arg-Pro-OHzAcOH (18) (GPRP, Pefabloc Pefa-6003
Pentapharm). Controls were effected in the absence of
agonists. After incubation for 15 min, the platelets were
fixed by adding paraformaldehyde 1% in phosphate buffered
saline (PBS; ratio 1:1) and incubated with mAbs CD62p,
CD63 and 7H2 at a final concentration of 10 mg/mL for
30 min. Controls were effected in the absence of primary
antibody using PBS. Bound antibody was measured using
fluorescein isothiocyanate (FITC)-conjugated F(ab9)2 frag-
ments of rabbit anti-mouse immunoglobulins (Dako) at a
final concentration of 1.5 mg/mL after incubation for
another 30 min.
Whole blood was used for PAC-1 platelet labeling,
diluted 1:20 with modified Tyrode’s buffer and aliquoted
into polypropylene tubes containing PAC-1-FITC anti-
body (20 mg/mL; Becton Dickinson) and agonists at the
predetermined final concentrations (ADP 0.01 to 10
mmol/L, collagen type I 25 to 75 mg/mL and thrombin 0.01
to 0.1 U/mL). The samples were incubated without stirring
for 15 min, platelets were fixed by adding cold paraformal-
dehyde 1% (ratio 1:5) and analyzed within 2 h on FACScan
(Becton-Dickinson). Fluorescence histograms were ob-
tained for 10,000 cells gated per sample, data being analyzed
using Cell Quest software (Becton-Dickinson). Antibody
binding was expressed as the percentage of platelets positive
for antibody. The gate for activated platelets was identified
by mAb 7H2 and was set so as to include ,1% of the events
seen when identical platelet samples were incubated with
the control murine immunoglobulin (IgM or IgG) used at
the same concentration as the murine mAb. Percentages of
activation of unstimulated platelets in PRP and whole blood
were as follows (given as mean 6 SEM): CD 62p, 1.0 6
0.1%; CD 63, 1.7 6 0.6% in PRP and PAC-1, 2.3 6 0.4%
in whole blood, respectively. These values are within our
normal ranges from blood samples obtained from normal
subjects.
Statistical analysis. Continuous variables were expressed
as mean 6 SEM. For comparisons between two treatment
regimens in the same patient group, we used the Wilcoxon
signed rank test. For comparison of the effects of different
agonist concentrations within treatment groups, the Fried-
mann test was used. A value of p , 0.05 was considered to
indicate a significant difference.
RESULTS
Platelet aggregation studies. As shown in Figure 1A, ex
vivo platelet aggregation was induced by addition of ADP 3,
6 and 20 mmol/L in a dose dependent manner (p , 0.001).
Adenosine diphosphate-induced aggregation was signifi-
cantly inhibited in patients treated with clopidogrel 75 mg
(p , 0.001) or clopidogrel 75 mg plus aspirin 100 mg (p ,
0.001) compared with aspirin 100 mg alone to a similar
extent at each ADP concentration. Regarding the dose of
aspirin, Figure 1B illustrates no difference in ADP-induced
aggregation in patients treated with aspirin 100 mg com-
pared with aspirin 300 mg and their combination with
clopidogrel 75 mg, respectively.
In contrast, mean values of dose-dependent platelet
aggregation induced by collagen 1.5, 4.0 and 40 mg/mL
were significantly higher in patients treated with clopidogrel
75 mg alone compared with aspirin 100 mg alone (p , 0.01,
Fig. 2). However, the combination of two drugs strongly
potentiated the antiaggregating effects of the monotherapies
at all agonist concentrations. The ED50 for collagen-
Figure 1. (A) Dose-dependent ADP-induced platelet aggregation (per-
centage of light transmission in platelet-rich plasma) in 30 patients treated
with aspirin 100 mg/day, clopidogrel 75 mg/day and aspirin 100 mg/day
plus clopidogrel 75 mg/day. Results represent mean 6 SEM. *p , 0.05
versus aspirin (Wilcoxon signed rank test). (B) Effects of different aspirin
doses on ADP-induced platelet aggregation (percentage of light transmis-
sion in platelet-rich plasma) in 12 patients with aspirin 100 mg/day, aspirin
300 mg/day, aspirin 100 mg/day plus clopidogrel 75 mg/day and aspirin
300 mg/day plus clopidogrel 75 mg/day. Results represent mean 6 SEM.
*p , 0.05 versus aspirin (Wilcoxon signed rank test). ADP 5 adenosine
diphosphate.
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induced platelet aggregation slightly decreased from 5.5 6
1.5 mg/mL in the aspirin 100 mg treated group to 2.5 6
0.4 mg/mL in the clopidogrel 75 mg group (p , 0.05) and
significantly increased to 22.4 6 4.0 mg/mL in patients
receiving the combined treatment (p , 0.001). Again, no
differences in collagen-induced platelet aggregation
(4 mg/mL) was seen between aspirin 100 mg and 300 mg
alone (31.7 6 7.7% vs. 33.0 6 5.1%) or their combination
with clopidogrel 75 mg, respectively (14.5 6 4.5% vs.
18.2 6 4.3%).
The thrombin receptor agonist peptide (TRAP) induced
aggregation was not significantly different at the lowest
agonist concentration (8 mmol/L) between all groups but
tended to be lower in the group with combined treatment at
the 10 mmol/L TRAP dose. At the 15 mmol/L TRAP dose
where half-maximal aggregations were surpassed, the com-
bination of aspirin 100 mg and clopidogrel 75 mg signifi-
cantly reduced platelet aggregation compared with aspirin
100 mg or clopidogrel 75 mg alone (Fig. 3). No difference
in TRAP-induced platelet aggregation (15 mmol/L) was
seen between aspirin 100 mg and 300 mg alone (61.2 6
3.8% vs. 58.0 6 3.9%, respectively) or their combination
with clopidogrel 75 mg (54.2 6 3.4% vs. 53.0 6 3.7%,
respectively).
Aspirin alone or in combination with clopidogrel fully
inhibited arachidonic acid-induced aggregation in all pa-
tients (3.6 6 0.6%), whereas clopidogrel alone did not
inhibit arachidonic induced aggregation (74 6 3.2%, p ,
0.001).
Activation markers after platelet stimulation. The ex-
pression and induction of CD62p indicating release reaction
of alpha-granules, CD63 indicating lysosome secretion and
PAC-1 directed against activation-dependent epitopes on
GPIIb/IIIa were measured as markers of platelet activation.
Interestingly, to achieve similar levels of activated platelets
after agonist stimulation, lower ADP and thrombin con-
centrations were required for PAC-1 compared with plate-
let P-selectin or CD63 mAbs.
As shown in Figure 4, A to C, clopidogrel alone or
combined with aspirin had a significant effect on the
percentage of platelets positive for the three mAbs when
compared with aspirin alone after stimulation with ADP.
The combined therapy compared with clopidogrel alone
equally suppressed the activation markers. These effects
were seen independently of the ADP concentration used.
When the groups treated with aspirin 100 mg and aspirin
300 mg were compared, the results were concordant for all
three antibodies showing no difference in platelet activation
except for a slightly lower P-selectin expression with aspirin
300 mg at the highest ADP concentration (100 mmol/L,
Fig. 5). There were no differences in levels of activation
epitopes for all three mAbs between the two doses of aspirin
when they were combined with clopidogrel.
Platelet activation after thrombin stimulation is illus-
trated in Figure 4, D to F. Clopidogrel alone or in
combination with aspirin compared with aspirin alone
considerably suppressed the levels of platelet activation as
measured by the three mAbs. In addition, the combination
therapy compared with clopidogrel or aspirin alone signif-
icantly decreased platelet P-selectin expression and degran-
ulation at low concentrations of thrombin, and a trend
towards a reduction persisted at high thrombin concentra-
tions. These effects of combined therapy on platelet activa-
tion were not seen with PAC-1 where full extent of
activation was achieved at intermediate to high concentra-
tions of thrombin. No differences in platelet activation levels
between the two aspirin groups were detected with CD 63,
CD 62p and PAC-1, except for CD 62p and CD 63
expression at the highest dose of thrombin representing
extensive platelet activation (80.8 6 1.3% vs. 72.1 6 2.4%
and 51.4 6 3.7% vs. 41.6 6 3.3% for aspirin 100 mg vs.
aspirin 300 mg [p , 0.05], respectively). However, activa-
Figure 2. Dose-dependent collagen-induced platelet aggregation (percent-
age of light transmission in platelet-rich plasma) in 30 patients treated with
aspirin 100 mg/day, clopidogrel 75 mg/day and aspirin 100 mg/day plus
clopidogrel 75 mg/day. Results represent mean 6 SEM. *p , 0.05 versus
aspirin; #p , 0.05 versus clopidogrel (Wilcoxon signed rank test).
Figure 3. Dose-dependent TRAP-induced platelet aggregation (percent-
age of light transmission in platelet-rich plasma) in 30 patients treated with
aspirin 100 mg/day, clopidogrel 75 mg/day and aspirin 100 mg/day plus
clopidogrel 75 mg/day. Results represent mean 6 SEM. *p , 0.05 versus
aspirin; #p , 0.05 versus clopidogrel (Wilcoxon signed rank test).
TRAP 5 thrombin receptor agonist peptide.
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tion levels for the three mAbs were identical for both aspirin
groups when combined with clopidogrel.
The expression of activation-dependent epitopes mea-
sured with the three mAbs were always lower than 20% after
activation with human or equine collagen type I with
concentrations of 25, 50, 75 mg/mL. Although a trend
towards lower levels of platelet activation was detected in
patients treated with clopidogrel alone or with the combi-
nation of clopidogrel with aspirin, the dose response curves
were too flat to elicit significant differences between groups
(data not shown). With our experimental conditions used,
analysis of flow cytometric histograms showed no interfer-
ence with microaggregate formation, suggesting that the
collagen types used in our study were not effective enough to
induce platelet activation. Alberio and Dale (19) recently
demonstrated that collagen-induced P-selectin expression
and upregulation of surface GP IIb/IIIa varies significantly
depending on the type of collagen used.
Regarding the safety of clopidogrel, two patients devel-
oped a skin rash, which was rapidly reversible after discon-
tinuation of the drug. Platelet count, hemoglobin concen-
tration and leucocyte count remained unchanged
throughout the study. There were no bleeding complica-
tions noted with each of the treatments.
DISCUSSION
This study in postmyocardial infarction patients demon-
strates that clopidogrel alone or in combination with aspirin
markedly inhibited ADP-mediated platelet aggregation in
platelet-rich plasma compared with monotherapy with as-
pirin. Moreover, clopidogrel in combination with aspirin
significantly reduced collagen-induced platelet aggregation
compared with both monotherapies, suggesting a synergistic
Figure 4. Changes in the expression of platelet activation epitopes after administration of aspirin (100 mg/day, black bars), clopidogrel (75 mg/day, white
bars) and aspirin (100 mg/day) plus clopidogrel (75 mg/day, hatched bars). In figures A to C, platelets were stimulated with adenosine diphosphate (ADP;
0.01, 0.1, 1, 10, 100 mmol/L) and in D to F with thrombin (0.01, 0.05, 0.1, 0.5 U/mL). After stimulation, activated platelets were detected by flow
cytometry with monoclonal antibodies directed against CD62p (P-selectin), which recognizes alpha-granule release, CD63 recognizing lysosome secretion
and PAC-1 detecting activated GP IIb-IIIa complex. Results (n 5 30) are expressed as the percentage of the total platelet population binding each
monoclonal antibody and represent mean 6 SEM. *p , 0.05 versus aspirin; #p , 0.05 versus clopidogrel; §p 5 0.054; ¶p 5 0.065 versus clopidogrel
(Wilcoxon signed rank test).
Figure 5. CD62p (P-selectin) positive platelets after stimulation with
ADP in 12 patients receiving two different doses of aspirin: aspirin
100 mg/day, aspirin 300 mg/day, aspirin 100 mg/day plus clopidogrel
75 mg/day and aspirin 300 mg/day plus clopidogrel 75 mg/day. Results
represent mean 6 SEM. *p , 0.05 aspirin 100 mg versus 300 mg
(Wilcoxon signed rank test). ADP 5 adenosine diphosphate.
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platelet inhibitory effect. In addition, the combined treat-
ment resulted in a mild inhibition of aggregation induced by
stimulation of platelet thrombin receptor and was more
effective in inhibiting platelet activation by thrombin. Both
doses of aspirin equally potentiated the platelet inhibitory
effects of clopidogrel.
Preliminary data indicate that full inhibition of platelet
activation is present after 2 to 6 h following oral adminis-
tration of a loading dose of 300 mg or 525 mg (20,21). The
maximal inhibition at 2 h is equivalent to that achieved by
a daily dose of 75 mg clopidogrel for seven days (21).
Results from a dose-finding study demonstrated that the
inhibition of platelet aggregation by clopidogrel was
concentration-dependent at low doses, but no differences
were seen in patients on daily clopidogrel doses of 50 mg,
75 mg and 100 mg for 7 or 28 days, indicating sustained and
plateauing effects during chronic administration at doses
higher than 50 mg (22). A clopidogrel dose of 75 mg was
chosen in our study and previously evaluated in the CAP-
RIE study (10). Although animal models suggest a dose-
dependent inhibition of platelet-mediated thrombosis by
clopidogrel, this effect is mostly seen within the first hours
of intravenous administration (13), whereas it plateaus at
intermediate doses after oral administration of clopidogrel
for six days as demonstrated by a model of stent and graft
thrombosis in baboons (11).
Mechanisms of combination antiplatelet therapy. Al-
though the exact mechanism is not known, the synergy
between clopidogrel and aspirin may be secondary to the
different platelet activation pathways inhibited by these
antiplatelet drugs. Our results suggest that simultaneous
antagonism of thromboxane A2 by aspirin and adenosine
diphosphate by clopidogrel resulted not only in inhibition of
arachidonic acid- and ADP-mediated platelet activation but
also in a reduction of collagen- and thrombin-induced
platelet activation. Collagen is an important compound of
the extracellular matrix of the vessel wall that is exposed
after injury. Collagen-induced platelet aggregation at low
doses is dependent on ADP release by activated platelets
(14), whereas at high concentrations it can become ADP-
independent, overcoming inhibition of aggregation by clo-
pidogrel monotherapy as shown by our findings.
Potent synergistic effects of clopidogrel and aspirin re-
garding the inhibition of collagen-induced aggregation,
direct release reaction of platelets and platelet thrombus
formation have also been demonstrated in preclinical trials
in rabbits (12) and nonhuman primates (11). Similar effects
were seen in a porcine model of high-shear induced stent
thrombosis (13). Moreover, in patients after stent implan-
tation, ticlopidine—a prodrug that inhibits platelet function
through inhibition of the ADP receptor—was found to have
synergistic platelet inhibitory effects when combined with
aspirin (23). Consistent with our results in patients after
MI, these effects were seen particularly in collagen-induced
aggregation but not in ADP-mediated aggregation.
Platelet activation and surface expression of adhesive
glycoproteins play a key role in MI (24) and in thrombotic
complications after coronary interventions (25,26). Evalua-
tion of platelet activation by flow cytometry uses monoclo-
nal antibodies that recognize membrane glycoproteins
present only on activated platelets. Previous studies showed
that significant platelet activation as measured by surface
expression of activated GP IIb/IIIa receptors and P-selectin
occurred in patients after acute coronary syndromes (27) and
in patients after stenting receiving anticoagulation therapy
compared with combined antiplatelet therapy with ticlopi-
dine and aspirin (26). Our findings in patients after MI
show that ADP-induced platelet activation measured with
three monoclonal antibodies is significantly reduced by
clopidogrel compared with aspirin, but platelet reactivity
was not reduced further after ingestion of clopidogrel and
aspirin compared with clopidogrel alone. However, a syn-
ergistic inhibitory effect on platelet alpha-granule and lyso-
some degranulation was observed using thrombin as a
strong agonist at lower concentrations, but the effect was
overpowered at higher concentrations. Since thrombin plays
a pivotal role in platelet thrombus formation (28), the
simultaneous administration of clopidogrel and aspirin may
be beneficial in blocking the effects of physiologic levels of
thrombin on platelets in patients with acute coronary
syndromes.
Safety. Regarding the safety, reduction in the dose of
aspirin is desirable because side effects, in particular those in
the gastrointestinal tract, are dose-related. As a separate part
of our study, we examined the antiplatelet effects of two
aspirin doses (100 mg and 300 mg) in combination with
clopidogrel 75 mg. Chronic administration of both doses of
aspirin prevents thromboxane production in platelets, and
available data suggest little if any difference in clinical
efficacy (1). Our results confirm that platelet aggregation
and reactivity is not dependent on the maintenance dose of
aspirin, particularly when it is combined with an ADP-
receptor antagonist. Both drugs lead to a sustained inhibi-
tion of platelet aggregation for the life span of the platelet
(14). Recently, a large clinical trial showed an excellent
safety profile of clopidogrel (10). Compared with aspirin it
showed fewer side effects, and the incidence of significant
neutropenia was 0.1% compared with a reported incidence
of 1–3% for ticlopidine in clinical trials (29). Preliminary
results from three nonrandomized trials (9,30,31) and the
Clopidogrel Aspirin Stent International Cooperative Study
trial (32) suggest that simultaneous administration of clo-
pidogrel plus aspirin is safer than ticlopidine plus aspirin
after coronary stent implantation. Although these studies
suggest similar efficacy of both regimens in reducing coro-
nary events after stenting, they were not sufficiently powered
to answer the question of equivalence.
Study limitations. There are several limitations of this
study, which was designed as a pilot investigation, and,
therefore, has a small sample size of patients with chronic
stable coronary disease. In addition, the study is a compar-
ative investigation of different treatments but is lacking an
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untreated control group. Although platelet reactivity was
measured at steady-state drug administration, treatment
periods were too short to assess long-term antiplatelet
effects. Despite its wide use, there are also inherent limita-
tions of ex vivo platelet aggregation studies, which are crude
indicators of what is happening in vivo. However, using
flow cytometric analysis as a second method for the evalu-
ation of platelet reactivity and inhibitory effects of antiplate-
let drugs, our findings were consistent with two indepen-
dent methods.
Conclusions. In this prospective clinical ex vivo platelet
study, we found that the combination of two antiplatelet
agents acting through different pathways had greater inhib-
itory effects on platelet aggregation and activation than
either agent alone in patients with chronic stable coronary
disease. Thus, the concept of dual antiplatelet treatment
with clopidogrel and aspirin is promising and deserves
further evaluation in large randomized trials for secondary
prevention in patients after acute MI or unstable angina.
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